




PHARMACEUTICAL 2018

iBio Inc.
Rank 248 of 342





PHARMACEUTICAL 2018

iBio Inc.
Rank 248 of 342



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 210% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 172% points.

The company's Economic Capital Ratio, given in the ranking table, is -2.6%, being 48% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	8,572
Cost of Goods Sold	0
Intangible Assets	1,823
Liabilities, Current	2,013
Liabilities, Non-Current	0
Other Assets	26
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	25,082
Other Net Income	-1,865
Other Revenues	394
Property and Equipment	25,589
Research and Development	4,117
Selling, General and Administrative Expense	10,551

Output Variable	Value in 1000 USD
Assets	36,010
Liabilities	27,095
Expenses	14,668
Revenues	394
Stockholders Equity	8,915
Net Income	-16,139
Comprehensive Net Income	-16,139
Economic Capital Ratio	-2.6%